In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007–2009 study

Abstract

The in vitro activity of ceftobiprole was evaluated against 15 011 clinical isolates obtained from patients in Canadian hospitals between 2007 and 2009. All Staphylococcus aureus were susceptible to ceftobiprole (MIC 90′s for methicillin-susceptible Staphylococcus aureus and methicillin-resistant Staphylococcus aureus of ≤1 μg/mL and 2 μg/mL, respectively). Ceftobiprole was active against penicillin-susceptible Streptococcus pneumoniae (MIC 90, ≤0.06 μg/mL), penicillin-resistant Streptococcus pneumoniae (MIC 90, 0.5 μg/mL), Streptococcus pyogenes (MIC 90, ≤0.06 μg/mL), Staphylococcus epidermidis (MIC 90, ≤1 μg/mL), and Enterococcus faecalis (MIC 90, ≤1 μg/mL). Over 90% of Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Citrobacter freundii, Proteus mirabilis, and Serratia marcescens isolates were inhibited by a ceftobiprole concentration of ≤1 μg/mL. Ceftobiprole was not active against extended-spectrum β-lactamase–producing Escherichia coli and K. pneumoniae. The in vitro activity of ceftobiprole versus Pseudomonas aeruginosa was similar to that of cefepime (MIC 90, 16 μg/mL). The broad spectrum of activity by ceftobiprole would support further study of this agent in the treatment of hospital-acquired infections.